Combination toxicity of etoposide (VP-16) and photosensitisation with a water-soluble aluminium phthalocyanine in K562 human leukaemic cells

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1570-1577

  Gantchev, T G ^a   Brasseur, N ^a   Van Lier, J E ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Combination therapy; Etoposide; Photosensitisation; Phthalocyanine; Synergy

Indexed keywords

DNA FRAGMENT; ETOPOSIDE;

APOPTOSIS; ARTICLE; CELL CYCLE PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG TOXICITY; HUMAN; HUMAN CELL; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL;

EID: 0029854111     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.591     Document Type: Article

References (33)

1. AGARWAL ML, LARKIN HE, ZAIDI SIA, MUKHTAR H AND OLEINICK NL. (1993). Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma cells. Cancer Res., 53, 5897-5902.
2. AISNER J AND LEE EJ. (1991). Etoposide. Current and future status. Cancer, 67, (suppl. I), 215-219.
3. BUETTNER GR. (1984). Thiyl radical production with hematoporphyrin derivative, cytsteine and light: a spin trapping study. FEBS Lett., 177, 295-299.
4. CHAMPLIN R AND GALE RP. (1987). Acute myelogenous leukemia: recent advances in therapy. Blood, 69, 1551-1562.
5. CHOU T-C AND TALALAY P. (1983). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. In Advances in Enzyme Regulation, Vol. 22, Weber G (ed.), pp. 27-55. Pergamon Press: Oxford.
6. DUBREZ L, GOLDWASSER F, GENNE P, POMMIER Y AND SOLARY E. (1995). The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia, 9, 1013-1024.
7. GANTCHEV TG AND VAN LIER JE. (1995). Catalase inactivation following photosensitization with tetrasulfonated metallophthalocyanines. Photochem. Photobiol., 62, 123-134.
8. GANTCHEV TG, VAN LIER JE, STOYANOVSKY DA, YALOWICH JC AND KAGAN VE. (1994a). Interactions of phenoxyl radical of antitumour drug, etoposide, with reductants in solution and in cell and nuclear homogenates: electron spin resonance and high-performance liquid chromatography. Methods Enzymol., 234, 631-642.
9. GANTCHEV TG, URUMOV IJ, HUNTING DJ AND VAN LIER JE. (1994b). Photocytotoxicity and intracellular generation of free radicals by tetrasulphonated Al- and Zn-phthalocyanines. Int. J. Radiat. Biol., 65, 289-298.
10. GANTCHEV TG, GOWANS BJ, HUNTING DJ, WAGNER JR AND VAN LIER JE. (1994c). DNA strand scission and base release photosensitized by metallo-phthalocyanines. Int. J. Radiat. Biol., 66, 705-716.
11. GANTCHEV TG, URUMOV IJ AND VAN LIER JE. (1994d). On the relationship between rate of uptake of photofrin and cellular responses to photodynamic treatment in vitro. Cancer Biochem. Biophys., 14, 23-34.
12. GLISSON BS AND ROSS WE. (1987). DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol. Ther., 32, 89-106.
13. HADDOCK MG, AMES MM AND BONNER JA. (1995). Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin. Proc., 70, 1053-1060.
14. HAIM N, NEMEC J, ROMAN J AND SINHA B. (1991). Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res., 47, 5835-5840.
15. HUNTING DJ, GOWANS BJ, BRASSEUR N AND VAN LIER JE. (1987). DNA damage and repair following treatment of V-79 cells with tetrasulfonated phthalocyanines. Photochem. Photobiol., 45, 769-773.
16. ISSEL BF, MUGGIA FM AND CARTER SK. (1984). Etoposide (VP-16). Current Status and New Developments. Academic Press: Orlando, U.S.A.
17. KAGAN VE, YALOWICH JC, DAY BW, GOLDMAN R, GANTCHEV TG AND STOYANOVSKY DA. (1994). Ascorbate is the primary reductant of the phenoxyl radical of etoposide in the presence of thiols both in cell homogenates and in model systems. Biochemistry, 33, 9651-9660.
18. KAUFMANN SH. (1989). Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 49, 5870-5878.
19. KRISHAN A, PAIKA K AND FREI, III, E. (1975). Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. J. Cell Biol., 66, 521-530.
20. LIU LF. (1989). DNA topoisomerase poisons as antitumour drugs. Annu. Rev. Biochem., 58, 351-375.
21. MANS DRA, RETÈL J, VAN MAANEN JMS, LAFLEUR MVM, VAN SCHAIK MA, PINEDO HM AND LANKELMA J. (1990). Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded ΦX174 DNA. Br. J. Cancer, 62, 54-60.
22. MANS DRA, LAFLEUR MVM, WESTMIJZE EJ, VAN MAANEN JMS, VAN SCHAIK MA, LANKELMA J AND RETÈL J. (1991). Formation of different reaction products with single- and double-stranded DNA by the ortho-quinone and the semi-quinone free radical of etoposide (VP-16-213). Biochem. Pharmacol. 42, 2131-2139.
23. MANS DRA, LAFLEUR MVM, WESTMIJZE EJ, HORN IR, BETS D, SCHUURHUIS GJ, LANKELMA J AND RETÈL J. (1992). Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Biochem. Pharmacol., 43, 1761-1768.
24. PENG Q, FARRANTS GW, MADSLIEN K, BOMMER JC, MOAN J, DANIELSEN HE AND NESLAND JM. (1991). Subcellular localization, redistribution and photoblenching of sulfonated aluminium phthalocyanines in human melanoma cell line. Int. J. Cancer. 49, 290-295.
25. 2+-ATPase via thiol oxidation by its phenoxyl radical. Arch. Biochem. Biophys., 321, 140-152.
26. 2) in homogeneous and microheterogeneous media. J. Photochem. Photobiol., B: Biology, 6, 49-59.
27. SINHA BK, ANTHOLINE WM, KALYANARAMAN B AND ELIOT HM. (1990). Copper ion-dependent oxy-radical mediated DNA damage from dihydroxy derivative of etoposide. Biochim. Biophys. Acta, 1096, 81-83.
28. VALERIOTE F AND LIU H-S. (1975). Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother. Res., 59, 895-900.
29. VAN MAANEN JMS, DE VRIES J, PAPPIE D, VAN DEN AKKER E, LAFLEUR MVM, RETÈL J, VAN DER GREEF J AND PINEDO HM. (1987). Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res., 47, 4658-4662.
30. VAN MAANEN JMS, RETÈL J, DE VRIES J AND PINEDO HM. (1988a). Mechanism of action of antitumor drug etoposide: a review. J. Natl Cancer Inst., 80, 1526-1533.
31. VAN MAANEN JMS, LAFLEUR MVM, MANS DRA, VAN DEN AKKER E, DE RUITER C, KOOTSTRA PR, PAPPIE D, DE VRIES J, RETÈL J AND PINEDO HM. (1988b). Effects of the ortho-quinone and catechol of the antitumor drug VP-16-213 on the biological activity of single-stranded and double-stranded ΦPX174 DNA. Biochem. Pharmacol., 37, 3579-3589.
32. WALKER PR, SMITH C, YOUDALE T, LEBLANC J, WHITFIELD JF AND SIKORSKA M. (1991). Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res., 51, 1078-1085.
33. YOKOMIZO A, ONO M, NANRI H, MAKINO Y, OHGA T, WADA M, OKAMOTO T, YODOI J, KUWANO M AND KOHNO K. (1995). Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res., 55, 4293-4296.